Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13909710 | 1.00 | RAB9A (0.55) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL1786727 | 0.98 | TDP1 (0.54) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL12608325 | 0.98 | TDP1 (0.54) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL29908236 | 0.92 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL13256446 | 0.92 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL10337042 | 0.92 | MAPT (0.64) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL19344706 | 0.90 | MAOB (0.50) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL3091241 | 0.90 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL30536704 | 0.90 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL25396585 | 0.90 | RAB9A (0.58) | RAB9AMAPTSMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021050612-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS | CIDARA THERAPEUTICS, INC. (US) | 2021-03-18 | — | — | WO | disclosed |